Candriam Luxembourg S.C.A. Sells 40,000 Shares of Zafgen, Inc. (ZFGN)

Candriam Luxembourg S.C.A. cut its position in shares of Zafgen, Inc. (NASDAQ:ZFGN) by 18.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 173,000 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Zafgen were worth $607,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 89,805 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 5,794 shares in the last quarter. Spark Investment Management LLC increased its stake in Zafgen by 49.5% in the second quarter. Spark Investment Management LLC now owns 282,200 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 93,500 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after buying an additional 447,964 shares in the last quarter. 52.09% of the stock is currently owned by institutional investors and hedge funds.

Shares of Zafgen, Inc. (NASDAQ ZFGN) opened at 3.41 on Wednesday. The firm’s market cap is $93.34 million. The company has a 50 day moving average price of $3.48 and a 200-day moving average price of $4.08. Zafgen, Inc. has a 52-week low of $2.89 and a 52-week high of $5.46.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the firm posted ($0.55) earnings per share. On average, analysts expect that Zafgen, Inc. will post ($2.23) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/16/candriam-luxembourg-s-c-a-sells-40000-shares-of-zafgen-inc-zfgn.html.

A number of analysts recently issued reports on ZFGN shares. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, May 10th. ValuEngine downgraded Zafgen from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Roth Capital started coverage on Zafgen in a research report on Thursday, April 20th. They issued a “buy” rating and a $9.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $24.25.

In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The shares were acquired at an average price of $3.39 per share, with a total value of $33,900.00. Following the transaction, the insider now owns 21,443 shares in the company, valued at $72,691.77. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 21.20% of the stock is currently owned by company insiders.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen, Inc. (NASDAQ:ZFGN).

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply